John Patrick Shannon Jr - Jan 3, 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: President and Chief Operating Officer
Signature: /s/ Beth Hecht, as Attorney-in-Fact
Stock symbol: XERS
Transactions as of: Jan 3, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/5/2022, 05:16 PM
Previous filing: Nov 12, 2021
Next filing: Aug 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Award	$0	+250K	+67.77%	$0.00	619K	Jan 3, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2	These shares include 5,081 shares that were purchased on June 30, 2021 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.

Remarks:

President and Chief Operating Officer